Following the first release last year, this morning (November 15), the Beijing Federation of Industry and Commerce once again released the 2019 "Top 100 Private Enterprises in Beijing", "Top 100 Private Enterprises in Science and Technology Innovation", "Top 100 Cultural Enterprises in Private Enterprises" and The list of "Top 100 Social Responsibility of Private Enterprises in Beijing" and related research reports. As a leader in biomedicine, Minhai Biology was successfully selected as the "2019 Beijing Top 100 Private Enterprises in Scientific and Technological Innovation". The general manager of Minhai Biology Zheng Haifa took the stage to receive awards as 10 outstanding enterprises and received a cordial reception from city leaders.
The relevant person in charge of the Beijing Federation of Industry and Commerce said that the threshold for the index system of the top 100 private enterprises in Beijing in 2019 will be further increased, and seven additional items such as "gross GDP per capita", "labor productivity of all employees" and "proportion of population with college education or above" will be added. Strengthened the finalist concept of "Top 100" instead of "Top 100", and at the same time, added seven major one-vote vetoes, such as "Major Ecological Destruction", "Major Environmental Pollution Matters", and "Major Production Safety Accidents" to strengthen the standard of first-best The high-quality development orientation is more prominent. And present the characteristics of innovation and upgrading, structural optimization, R & D investment growth and so on.
Minhai Biology focuses on the research, development, production and sales of human vaccines. With the mission of "creating better vaccines and benefiting human health", it has always been diligent in innovation and brave in exploration. The selection of Minhai Biology in the "2019 Beijing Private Enterprises Top 100 Technology Innovation List" fully demonstrates the strength of enterprise technology innovation.